FDA-APPROVED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS
 
Generic & Class Brand & Company Strength Form Usual Dose*
Angiogenesis inhibitor
bevacizumab Avastin
(Genentech)		 100mg, 400mg soln for IV infusion after dilution 15mg/kg once every 3 weeks
Antimetabolites
gemcitabine Gemzar
(Lilly)

 

 200mg, 1g pwd for IV infusion after reconstitution 1000mg/m2 on Days 1, 8, and 15 of each 28 day cycle; or 1250mg/m2 on Days 1 and 8 of each 21 day cycle 
methotrexate Methotrexate injection
(Bedford)		 25mg/mL soln for IV, IM, intra-arterial, or intrathecal administration after dilution See drug entry and manufacturer's literature
1g pwd for IV, IM, intra-arterial, or intrathecal administration after dilution
Trexall
(Duramed)		 5mg, 7.5mg, 10mg, 15mg scored tabs
pemetrexed Alimta
(Lilly)		 500mg pwd for IV inj after reconstitution and dilution 500mg/m2 on Day 1 of each 21-day cycle
Antimicrotubule agents
docetaxel Taxotere
(Sanofi Aventis)		 40mg/mL soln for IV infusion after dilution 75mg/m2 once every 3 weeks
paclitaxel Taxol
(Bristol Myers Squibb)		 6mg/mL soln for IV administration after dilution 135mg/m2 every 3 weeks
vinorelbine Navelbine
(Pierre Fabre)

 

 10mg/mL soln for IV inj after dilution Monotherapy: 30mg/m2 once weekly Combination therapy: 25mg/m2 once weekly given every 4 weeks; or 30mg/m2 once weekly given on Days 1 and 29, then every 6 weeks
Photosensitizing agent
porfimer Photofrin
(Aptalis Pharmaceutical Technologies)		 75mg pwd for IV inj after reconstitution 2mg/kg then illumination with laser light 40–50 hours following injection
Tyrosine Kinase Inhibitors
crizotinib Xalkori
(Pfizer)		 200mg, 250mg caps 250mg twice daily
erlotinib Tarceva
(Genentech)		 25mg, 100mg, 150mg tabs 150mg once daily
gefitinib Iressa
(AstraZeneca)		 250mg tabs 250mg once daily
NOTES

* For more detailed dosing information, see drug entry

(Rev. 2/2012)